Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (SE:IMMNOV)
:IMMNOV
IMMNOV Stock Chart & Stats
kr0.33
-kr0.02(-4.98%)
At close: 4:00 PM EST
kr0.33
-kr0.02(-4.98%)
Day’s Range― - ―
52-Week Rangekr0.19 - kr0.81
Previous CloseN/A
Volume868.16K
Average Volume (3M)6.67M
Market Cap
kr209.28M
Enterprise Valuekr93.16M
Total Cash (Recent Filing)kr29.27M
Total Debt (Recent Filing)kr467.00K
Price to Earnings (P/E)―
Beta-0.83
Next Earnings
Nov 19, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding639,991,900
10 Day Avg. Volume4,471,906
30 Day Avg. Volume6,667,554
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.19 and its highest was kr0.81 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr209.28M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 19, 2025 which is in 26 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 28, 2025. The company reported -kr0.109 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.109.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.05.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 639,991,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.109 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -26.466%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
Company Description
Immunovia AB
Immunovia AB (IMMNOV) is a Swedish company specializing in the development and commercialization of diagnostic tools for complex forms of cancer and autoimmune diseases. The company focuses on utilizing its proprietary technology platform, IMMray, to enable early detection and improve treatment outcomes. Immunovia’s flagship product is the IMMray PanCan-d test aimed at early detection of pancreatic cancer, which is known for its low survival rates due to late diagnosis.
IMMNOV Company Deck
IMMNOV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in test development and financial management, with successful analytical validation and a promising rights issue. However, challenges remain with increased cash burn, limited initial revenue, and regulatory hurdles. The company is optimistic about its strategic plans for 2025, particularly the U.S. launch.View all SE:IMMNOV earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―
Options Prices
Currently, No data available
---